1. Hunt K. The basic social process of the menopausal transition. Journal of the Royal College of General Practice 2009: 398-401.
2. Deeks A A and McCabe M P. Well-being and menopause. Quality of Life Research 2009; 389-398.
3. Abbas SZ, Sangawan V, Das A, Pandey AK. Assessment of cardiovascular risk in natural and surgical menopause. Indian Journal of Endocrinology and Metabolism 2018; 22(2):223.
4. Lima R, Wofford M, Reckelhoff JF. Hypertension in postmenopausal women. Current Hypertension Reports 2012; 14(3):254-60.
5. Barton M, Meyer MR. Postmenopausal hypertension: mechanisms and therapy. Hypertension 2009; 54(1):11-8.
6. Ha H, Oh EY, Lee HB. The role of plasminogen activator inhibitor 1 in renal and cardiovascular diseases. Nature Reviews Nephrology 2009; 5(4):203.
7. Hoekstra T, Geleijnse JM, Schouten EG, Kluft C. Plasminogen activator inhibitor-type 1: its plasma determinants and relation with cardiovascular risk. Thrombosis and Haemostasis 2004; 91(05):861-72.
8. Tabak O, Gelisgen R, Uzun H, Kalender B, Balci H, Curgunlu A, Simsek G, Karter Y. Hypertension and hemostatic/fibrinolytic balance disorders. Clinical and Investigative Medicine 2009: 285-92.
9. Savoia C, Sada L, Zezza L, Pucci L, Lauri FM, Befani A, Alonzo A, Volpe M. Vascular inflammation and endothelial dysfunction in experimental hypertension. International Journal of Hypertension 2011. 281240.
10. De Taeye B, Smith LH, Vaughan DE. Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease. Current Opinion in Pharmacology 2005; 5(2):149-54.
11. Cottone S, Mulè G, Nardi E, Vadalà A, Lorito MC, Guarneri M, et al. C-reactive protein and intercellular adhesion molecule-1 are stronger predictors of oxidant stress than blood pressure in established hypertension. Journal of Hypertension 2007; 25(2):423-8.
12. Iellamo F, Volterrani M. Effect of exercise training in essential arterial hypertension. A Revista Brasileira de Hipertensão 2010; 17(2):68-71.
13. Guimarães GV, Ciolac EG, Carvalho VO, D'Avila VM, Bortolotto LA, Bocchi EA. Effects of continuous vs. interval exercise training on blood pressure and arterial stiffness in treated hypertension. Hypertension Research 2010; 33(6):627.
14. Khalaf D, Krüger M, Wehland M, Infanger M, Grimm D. The effects of oral l-arginine and l-citrulline supplementation on blood pressure. Nutrients 2019; 11(7):1679.
15. Elwahaab HA, Hagag AA, Rahmy AF, Fares HM, Fouad SA. Effect of Aerobic exercises on Blood coagulation and Fibrinolysis factors in Elderly Hypertensive patients. Journal of Advanced Pharmacy Education & Research 2019; 9(1):44-48.
16. Esmat S, Al Salam RA, Rashed L. Effect of exercise on plasminogen activator inhibitor-1 (PAI-1) level in patients with metabolic syndrome. Journal of American Science 2010; 6(12):1374-80.
17. Bodary PF, Yasuda N, Watson DD, Brown AS, Davis JM, Pate RR. Effects of short-term exercise training on plasminogen activator inhibitor (PAI-1). Medicine and Science in Sports and Exercise 2003; 35(11):1853-8.
18. Zoppini G, Targher G, Zamboni C, Venturi C, Cacciatori V, Moghetti P, Muggeo M. Effects of moderate-intensity exercise training on plasma biomarkers of inflammation and endothelial dysfunction in older patients with type 2 diabetes. Nutrition, Metabolism and Cardiovascular Diseases 2006; 16(8):543-9.
19. Donley DA, Fournier SB, Reger BL, DeVallance E, Bonner DE, Olfert IM, Frisbee JC, Chantler PD. Aerobic exercise training reduces arterial stiffness in metabolic syndrome. Journal of Applied Physiology 2014; 116(11):1396-404.
20. Hansen AH, Nielsen JJ, Saltin B, Hellsten Y. Exercise training normalizes skeletal muscle vascular endothelial growth factor levels in patients with essential hypertension. Journal of Hypertension 2010; 28(6):1176-85.
21. Mortensen SP, Nyberg M, Gliemann L, Thaning P, Saltin B, Hellsten Y. Exercise training modulates functional sympatholysis and α‐adrenergic vasoconstrictor responsiveness in hypertensive and normotensive individuals. The Journal of Physiology 2014; 592(14):3063-73.
22. Ammar T. Effects of aerobic exercise on blood pressure and lipids in overweight hypertensive postmenopausal women. Journal of Exercise Rehabilitation 2015; 11(3):145-150.
23. Jablecka A, Bogdanski P, Balcer N, Cieslewicz A, Skoluda A, Musialik K. The effect of oral L-arginine supplementation on fasting glucose, HbA1c, nitric oxide and total antioxidant status in diabetic patients with atherosclerotic peripheral arterial disease of lower extremities. European Review for Medical and Pharmacological Sciences 2012; 16(3):342-50.
24. Catena C, Colussi G, Fagotto V, Sechi LA. Decreased fibrinolytic activity is associated with carotid artery stiffening in arterial hypertension. Journal of research in medical sciences: Journal of Isfahan University of Medical Sciences 2017;22: 57.
25. Naya M, Tsukamoto T, Inubushi M, Morita K, Katoh C, Furumoto T, et al. Elevated plasma plasminogen activator inhibitor type-1 is an independent predictor of coronary microvascular dysfunction in hypertension. Circulation Journal 2007; 71(3):348-53.
26. Srikumar N, Brown NJ, Hopkins PN, Jeunemaitre X, Hunt SC, Vaughan DE, Williams GH. PAI-1 in human hypertension: relation to hypertensive groups. American Journal of Hypertension. 2002; 15(8):683-90.
27. Braschi A. Acute exercise-induced changes in hemostatic and fibrinolytic properties: analogies, similarities, and differences between normotensive subjects and patients with essential hypertension. Platelets 2019; 30(6):675-89.
28. Kaikita K, Fogo AB, Ma L, Schoenhard JA, Brown NJ, Vaughan DE. Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition. Circulation 2001; 104(7):839-44.
29. 29. Garg MK, Dutta MK, Mahalle N. Adipokines (adiponectin and plasminogen activator inhhibitor-1) in metabolic syndrome. Indian Journal of Endocrinology and Metabolism 2012; 16(1):116-123.
30. Barnard SA, Pieters M, De Lange Z. The contribution of different adipose tissue depots to plasma plasminogen activator inhibitor-1 (PAI-1) levels. Blood Reviews 2016; 30(6):421-9.
31. Mirmiran P, Bahadoran Z, Ghasemi A, Azizi F. The association of dietary L-arginine intake and serum nitric oxide metabolites in adults: a population-based study. Nutrients 2016; 8(5):311.
32. Litvinova L, Atochin DN, Fattakhov N, Vasilenko M, Zatolokin P, Kirienkova E. Nitric oxide and mitochondria in metabolic syndrome. Frontiers in Physiology 2015; 6:20.
33. Bahrami D, Mozaffari-Khosravi H. The Effect of Oral L-arginine Supplementation on Blood Pressure in Patients with Metabolic Syndrome: A Randomized Clinical Trial. Iranian Journal of Diabetes and Obesity 2018; 10(1):1-0.
34. Martina V, Masha A, Gigliardi VR, Brocato L, Manzato E, Berchio A, et al. Long-term N-acetylcysteine and L-arginine administration reduces endothelial activation and systolic blood pressure in hypertensive patients with type 2 diabetes. Diabetes Care 2008; 31(5):940-4.
35. Rajapakse NW, Mattson DL. Role of L‐arginine in nitric oxide production in health and hypertension. Clinical and Experimental Pharmacology and Physiology 2009; 36(3):249-55.
36. D'Acquisto F, Maiuri M, de Cristofaro F, Carnuccio R. Nitric oxide prevents inducible cyclooxygenase expression by inhibiting nuclear factor-κB and nuclear factor-interleukin-6 activation. Naunyn-Schmiedeberg's Archives of Pharmacology 2001; 364(2):157-65.
37. Cornelissen VA, Fagard RH. Effects of endurance training on blood pressure, blood pressure–regulating mechanisms, and cardiovascular risk factors. Hypertension 2005; 46(4):667-75.